Side effect profiles in published research depend on dose, route, and model system
Over the next five years, well almost certainly have better human trials, clearer safety data and a much better understanding of where BPC-157 genuinely has a place in medicine and where it doesnt. That may ultimately prove to be the real story
Not intended to diagnose, treat, cure, or prevent any disease
Histopathological findings revealed preservation of neural architecture, with reduced axonal degeneration, diminished neuronal loss, and limited formation of cystic cavities, suggesting an attenuation of secondary injury processes (12)
As the newest weight-loss drug on the scene, retatrutide targets three receptors: GLP-1, GIP and glucagon